Fig. 7

ANXA6 promotes autophagy and metastatic ability in HNSCC cells by regulating TRPV2. A Correlation between TRPV2 and ANXA6 according to the TCGA database of HNSCC. B Comparisons of overall survival between low TRPV2 expression group and high TRPV2 expression group in HNSCC patients using GEO database (GSE31056 and GSE27020). C The association between TRPV2 expression and mortality in HNSCC patients. D Relative mRNA expression levels of TRPV2 in HNSCC cells after overexpression ANXA6. E The protein expression levels of TRPV2 and ANXA6 in HNSCC cells after overexpression of ANXA6. F Representative transmission electron microscope (TEM) images of autophagosomes in ANXA6-overexpressed FaDu cell line and treated with siTRPV2. Magnification: ×25,000 for low-power fields, ×5000 for high-power fields. G Representative immunofluorescent images of the colocalization about LC3 (red) and LAMP1 (green) in ANXA6-overexpressed FaDu cell line and treated with siTRPV2. H The protein expression levels of P62, LC3, and TRPV2 in the ANXA6-overexpressed FaDu cell line treated with siTRPV2. I The protein expression levels of p-AKT, AKT, p-mTOR, and mTOR in ANXA6-overexpressed FaDu cell line and treated with siTRPV2. J, K Transwell assay (J) and wound healing assay (K) were used to assess the migration and invasion abilities in the ANXA6-overexpressed FaDu cell line and treated with siTRPV2. L The expression intensity of TRPV2 in HNSCC with lymphatic metastasis in vivo. M. The correlation analysis for expression intensity of TRPV2 and ANXA6 in 78 HNSCC clinical specimens. Data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; compared with the indicated group